Global burden of hepatitis B virus: current status, missed opportunities and a call for action
Chronic hepatitis B virus (HBV) infection affects about 296 million people worldwide and is
the leading aetiology of cirrhosis and liver cancer globally. Major medical complications also …
the leading aetiology of cirrhosis and liver cancer globally. Major medical complications also …
New approaches to chronic hepatitis B
G Dusheiko, K Agarwal, MK Maini - New England Journal of …, 2023 - Mass Medical Soc
New Approaches to Chronic Hepatitis B | New England Journal of Medicine Skip to main content
The New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …
The New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …
Current trend in antiviral therapy for chronic hepatitis B
RN Chien, YF Liaw - Viruses, 2022 - mdpi.com
Since active hepatitis B virus (HBV) replication is the key driver of hepatic necroinflammation
and disease progression, the treatment aim of chronic hepatitis B (CHB) is to suppress HBV …
and disease progression, the treatment aim of chronic hepatitis B (CHB) is to suppress HBV …
[HTML][HTML] Serious adverse events after cessation of nucleos (t) ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis
Background & Aims The risk of serious clinical outcomes following cessation of nucleos (t)
ide analogues (NUCs) in individuals with chronic hepatitis B remains poorly characterized …
ide analogues (NUCs) in individuals with chronic hepatitis B remains poorly characterized …
Hepatocellular carcinoma reduced, HBsAg loss increased, and survival improved after finite therapy in hepatitis B patients with cirrhosis
WJ Jeng, RN Chien, YC Chen, CL Lin, CY Wu… - Hepatology, 2024 - journals.lww.com
Hepatocellular carcinoma reduced, HBsAg loss increased, and... : Hepatology Hepatocellular
carcinoma reduced, HBsAg loss increased, and survival improved after finite therapy in hepatitis …
carcinoma reduced, HBsAg loss increased, and survival improved after finite therapy in hepatitis …
[HTML][HTML] Past, present, and future of long-term treatment for hepatitis B virus
T Broquetas, JA Carrión - World Journal of Gastroenterology, 2023 - ncbi.nlm.nih.gov
The estimated world prevalence of hepatitis B virus (HBV) infection is 316 million. HBV
infection was identified in 1963 and nowadays is a major cause of cirrhosis and …
infection was identified in 1963 and nowadays is a major cause of cirrhosis and …
Severe hepatitis B flares with hepatic decompensation after withdrawal of nucleos (t) ide analogues: a population‐based cohort study
Background Finite nucleos (t) ide analogue (NUC) therapy has been proposed as an
alternative treatment strategy for chronic hepatitis B (CHB). Aim To quantify the incidence of …
alternative treatment strategy for chronic hepatitis B (CHB). Aim To quantify the incidence of …
Activating adaptive immunity by bispecific, T-cell engager antibodies bridging infected and immune-effector cells is a promising novel therapy for chronic hepatitis B
Z **e, U Protzer - Antiviral Research, 2024 - Elsevier
Bispecific antibodies (bsAbs) are engineered immunoglobulins that combine two different
antigen-binding sites in one molecule. BsAbs can be divided into two molecular formats: IgG …
antigen-binding sites in one molecule. BsAbs can be divided into two molecular formats: IgG …
Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort
Introduction Both entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are first-line
therapies for chronic hepatitis B (CHB), but their comparative effectiveness with regards to …
therapies for chronic hepatitis B (CHB), but their comparative effectiveness with regards to …
[HTML][HTML] Safety considerations for withdrawal of nucleos (t) ide analogues in patients with chronic hepatitis B: First, do no harm
Nucleos (t) ide analogues (NA) are widely used to treat hepatitis B virus (HBV) infection, but
they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set at …
they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set at …